Sponsored by Labcorp
That first prenatal appointment often comes with a long list of bloodwork and screenings. It's exciting, sure, but it can also feel overwhelming fast. Suddenly, there's a stack of test names, acronyms, and timelines, and not a lot of breathing room to figure out what each one actually means.
Cell-free DNA screening is one of those options that tends to raise eyebrows. It's newer than other methods of prenatal screening, it sounds very science-heavy, and it's often introduced quickly in conversation. That can leave a lot of people wondering what it actually does and whether it's something they should say yes to.
Asking questions here isn't overthinking. It's advocating for yourself and your baby, and that matters.
Cell-free fetal DNA screening explained
Cell-free DNA prenatal screening, often shortened to cfDNA screening or referred to as non-invasive prenatal testing (NIPT), looks for tiny fragments of DNA that circulate in the blood during pregnancy. These fragments come from the placenta and usually match the baby's genetic makeup.
During pregnancy, both DNA fragments from the mom (maternal) and from the baby (placental) float freely in the bloodstream. A lab can analyze a blood sample to look at those fragments for patterns that suggest certain chromosomal differences and the overall health of the pregnancy.
This approach is now the standard of care and is more advanced than older screening methods that relied on hormone levels or ultrasound measurements alone. cfDNA screening is considered non-invasive because it only requires a blood draw from the pregnant person's arm. There's no needle near the uterus and no direct contact with the pregnancy itself.
The technology became more widely available in the early 2010s and has since become a common option in most OB and midwifery practices. The innovation here is simple but powerful: getting detailed genetic screening information without increasing the risk to the pregnancy.
Cell-free DNA Prenatal Screening vs. NIPT (they're actually the same thing)
The names can be confusing, but cell-free prenatal DNA screening and NIPT screening both refer to the same type of screening.
What can cfDNA screen for?
Cell-free DNA screening looks for common chromosome conditions, in particular conditions with an extra chromosome (trisomy). Additionally, some offices may offer screening for very small deletions in specific regions of a chromosome (microdeletion) and for the health of the pregnancy, for which the vast majority of pregnancies (>95%) are unaffected.
In the rare cases of an affected pregnancy, the more common abnormalities are trisomy 21, followed by extra or missing X or Y chromosomes (sex chromosomes), 22q microdeletion, and trisomy 18. Most other trisomies and microdeletions are incredibly rare.
Most cfDNA screening looks for:
Trisomy 21, which causes Down syndrome
Trisomy 18 and trisomy 13, rarer but more serious chromosomal conditions
Extra or missing X or Y chromosomes (sex chromosome conditions), such as Turner syndrome or Klinefelter syndrome
Some versions also screen for specific microdeletions, which are very small missing pieces of chromosomes. Not all providers recommend microdeletion screening because the reliability of results varies by condition.
The American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) don't currently recommend routine microdeletion screening, citing insufficient clinical validation and low positive predictive value compared to some other conditions.
cfDNA screening doesn't screen for neural tube defects like spina bifida, heart defects, or most structural differences. That's why anatomy ultrasounds and other blood tests are still part of routine prenatal care.
The most important distinction is that cfDNA is a screening test, not a diagnostic one. It estimates risk but doesn't confirm a diagnosis.
Testing for Down syndrome
cfDNA screening has a very high detection rate for trisomy 21. The NEXT study, published in the New England Journal of Medicine in 2015, enrolled 15,841 pregnancies across 35 centers in six countries. It found that cfDNA screening identified 100% of trisomy 21 cases in the cohort, compared to 78.9% with standard first-trimester screening.
A 2017 meta-analysis published in Ultrasound in Obstetrics & Gynecology calculated pooled sensitivity and specificity for trisomy 21 detection at 99.7% and 99.96%, respectively, across multiple large clinical validity studies.
A high-risk result doesn't mean a baby definitely has Down syndrome. It means follow-up diagnostic testing, such as chorionic villus sampling (CVS) or amniocentesis, may be offered to confirm the finding.
One benefit of cfDNA screening is that it reduces the number of people who receive invasive diagnostic procedures that may not be necessary.
Finding out sex
Many cfDNA screens can also report fetal sex by analyzing sex chromosomes. Studies have reported NIPT sensitivities for fetal sex determination of greater than 95% and specificity of 98.6% when adequate fetal DNA is present in the sample.
Getting this information is, of course, optional. Some people want to know early, and others prefer to wait or skip it entirely. Both choices are valid.
Can a cell-free DNA screening be wrong for sex?
Errors are rare, but they can happen. Situations that can affect results include:
A vanishing twin early in pregnancy
Certain maternal sex chromosome variations
Very low fetal DNA levels
Overall, cfDNA screening has not only become the standard of care, according to ACOG's Practice Bulletin, but it also remains one of the most reliable ways to determine fetal sex before birth.
Cell-free fetal DNA screening: timing and process
Most providers offer cfDNA screening starting at nine to 10 weeks of pregnancy, according to ACOG's Practice Bulletin. That timing matters because there needs to be enough placental DNA in the bloodstream (known as the fetal fraction) for analysis.
Results typically come back within less than a week. Waiting can feel long, especially when anxiety is already high, and that's a very normal response.
How is the test performed?
Questions Women Are Asking
The process itself is straightforward. A standard blood draw is taken from the arm, with no fasting or special preparation required ahead of time.
Once the sample is collected, it's sent to a specialized laboratory where advanced sequencing methods are used to analyze the DNA fragments. Behind the scenes, the lab sequences the cfDNA fragments, measures the fetal fraction, and compares chromosomal patterns to expected norms to assess risk.
Reliability of cell-free DNA screening (the numbers matter)
Screening test performance is often described using the terms "sensitivity" and "specificity." Sensitivity reflects how well the test detects a condition when it's present. Specificity reflects how well it avoids false positives.
For trisomy 21, sensitivity and specificity both exceed 99% in most large studies. Detection rates for trisomy 18 and 13 are slightly lower but still very high.
False-positive and false-negative results can occur with any screening test, including cfDNA. A healthcare provider can discuss (before or after screening) whether factors like maternal weight, twin gestation, low fetal fraction, or certain medications may affect the results.
Who should consider cell-free DNA screening?
Originally, cfDNA screening was offered mainly to people over age 35 or those with higher-risk pregnancies. That's changed.
In 2020, the ACOG and SMFM jointly updated their guidance to recommend that prenatal screening options (including cfDNA screening) be discussed and offered to all pregnant patients regardless of maternal age or baseline risk. ACOG specifically notes that cfDNA is "the most sensitive and specific screening test for the common fetal aneuploidies."
Anyone can consider cfDNA screening, including if they:
Are 35 or older at delivery
Had abnormal results on earlier screening
Have a personal or family history of chromosomal conditions
Want as much information as possible early on
Insurance coverage varies, and personal comfort with uncertainty also plays a role. There's no single right answer here.
Cell-free DNA screening cost
Insurance coverage for cfDNA screening has expanded in recent years. Many labs offer out-of-pocket caps or financial assistance programs. Recent data suggests that ?70% of patients now pay $0 for this testing, and >80% pay less than $200.
Labcorp works with healthcare providers to integrate cfDNA screening into routine care and offers transparent pricing tools so patients can understand potential costs ahead of time. That kind of clarity can make decision-making feel less stressful.
Understanding your results (and what happens next)
A low-risk result means the likelihood of the screened conditions is low, not zero. Routine prenatal care continues as planned.
A high-risk result means further discussion and follow-up testing are recommended. Genetic counseling is often offered to help interpret results and talk through next steps.
Sometimes, results come back as "no-call" or "non-reportable." One common reason for this result is that there wasn't enough fetal DNA to analyze. This doesn't mean anything is wrong. It often leads to a repeat test later on.
Emotional reactions to results vary widely. Support and clear communication make a real difference.
Making the decision that's right for you
Choosing prenatal screening is personal. Some people want every possible data point. Others prefer less information unless there's a clear medical need.
Helpful questions to ask include:
What would be done with different types of results?
Would the information change care decisions?
How much uncertainty feels manageable?
Declining testing is always an option. There's no moral or medical obligation to say yes.
Where to get cell-free DNA screening
Most people access cfDNA screening through their OB/GYN, midwife, or maternal-fetal medicine specialist. The test may be performed at an independent lab, like Labcorp, or at a lab that's part of a hospital or health system.
Clinicians should consider several factors when choosing a lab, including lab accreditation, experience, and whether it offers access to genetic counseling. Genetic counseling can provide valuable information to help understand test results and guide next steps.
The real value of cell-free DNA screening
Cell-free DNA screening offers early, detailed screening information with no added risk to the pregnancy. For many, it brings reassurance. For others, it opens the door to more informed conversations and planning.
You deserve answers that are reliable, accessible, and explained in plain language — not buried in acronyms or delivered without context. When you're ready to take that next step, Labcorp offers comprehensive cfDNA screening options, with a team of genetic counselors available to help you and your provider make sense of what the results mean and what comes next.
Learn more about Labcorp's preconception and prenatal screening options.
